Neuberger Berman Group LLC Krystal Biotech, Inc. Transaction History

Neuberger Berman Group LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$39.81 - $88.24 $1.8 Million - $3.99 Million	-45,246 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$52.01 - $71.77 $30,321 - $41,841	583 Added 1.31%	45,246 $2.35 Million
Q2 2021 Aug 13, 2021	BUY	$62.14 - $81.82 $37,470 - $49,337	603 Added 1.37%	44,663 $3.03 Million
Q1 2021 May 13, 2021	SELL	$59.42 - $85.46 $412,374 - $593,092	-6,940 Reduced 13.61%	44,060 $3.39 Million
Q3 2020 Nov 12, 2020	BUY	$37.76 - $48.49 $302,080 - $387,920	8,000 Added 18.6%	51,000 $2.2 Million
Q2 2020 Aug 13, 2020	BUY	$37.03 - $60.0 $666,540 - $1.08 Million	18,000 Added 72.0%	43,000 $1.78 Million
Q1 2020 May 14, 2020	SELL	$35.02 - $65.64 $546,312 - $1.02 Million	-15,600 Reduced 38.42%	25,000 $1.08 Million
Q3 2019 Nov 13, 2019	BUY	$34.72 - $51.3 $861,056 - $1.27 Million	24,800 Added 156.96%	40,600 $1.41 Million
Q2 2019 Aug 13, 2019	BUY	$27.2 - $41.2 $171,360 - $259,560	6,300 Added 66.32%	15,800 $636,000
Q1 2019 May 13, 2019	BUY	$19.86 - $32.9 $188,670 - $312,550	9,500 New	9,500 $313,000

266

25M

270K

172K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.55B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.